MADRIGAL PHARMACEUTICALS, INC.

MDGL · Biotech · Nasdaq · As of 10 Sep 2026

FundamentalsNot enough data yet
ValueNot enough data yet
News flowBalanced
MomentumStrong
SafetyStrong

Overall confidence 38/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Medium (18/100) · Gap confidence 55/100Some evidence isn't yet fully priced in.

This month at a glance

AIR Score™ change: +2Moved up +2 on new evidence.

Cycle window9 Sep 2026 → 10 Sep 2026

Momentum+2Contributed positively to the latest score.

Evidence timeline

[8-K 5.02] MADRIGAL PHARMACEUTICALS, INC. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Aug 11, 2026 · 8-K
[8-K 2.02] MADRIGAL PHARMACEUTICALS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Jul 30, 2026 · 8-K
[8-K 5.02] MADRIGAL PHARMACEUTICALS, INC. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Jun 16, 2026 · FORM 8-K
[8-K 2.02] MADRIGAL PHARMACEUTICALS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 6, 2026 · 8-K
[8-K 5.02] MADRIGAL PHARMACEUTICALS, INC. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Apr 22, 2026 · 8-K
[8-K 2.02] MADRIGAL PHARMACEUTICALS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Feb 19, 2026 · 8-K
[8-K 1.01] MADRIGAL PHARMACEUTICALS, INC. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Jan 29, 2026 · FORM 8-K
[8-K 5.02] MADRIGAL PHARMACEUTICALS, INC. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Dec 5, 2025 · 8-K
[8-K 2.02] MADRIGAL PHARMACEUTICALS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Nov 4, 2025 · 8-K
[8-K 2.02] MADRIGAL PHARMACEUTICALS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 5, 2025 · 8-K
[8-K 1.01] MADRIGAL PHARMACEUTICALS, INC. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Jul 17, 2025 · 8-K
[8-K 1.02] MADRIGAL PHARMACEUTICALS, INC. — Termination of a Material Definitive AgreementSEC · SEC EDGAR
Jul 17, 2025 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.